adpbe stock photos - David A Litman Bayer AG’s Pharmaceuticals division in Berlin has expanded its oncology pipeline through a licensing and collaboration agreement with US-based Kumquat Biosciences Inc., which may yield up to US$1.3bn in total consideration. Should Kumquat successfully complete its high-risk Phase Ia clinical study targeting the common KRAS G12D mutation, Bayer will assume responsibility for further development and global commercialisation of the candidate.
Tag Archive for: cancer
Jovanche Vitanovski/123rf.comParis-based One Biosciences, a pioneering “techbio” company at the intersection of artificial intelligence and oncology, has announced a €15 million Series A funding round to accelerate the clinical application of its flagship technology.
BioNTechBioNTech is set to open a research centre for cancer therapy in the United Kingdom, much to the delight of the British government, which is helping pave the way with a substantial financial boost.
adobe stock - JHVEPhoto Boehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments.
adobe stock - peterschreiber.mediaThe British company Semarion Ltd and US start-ups n6 Tec Inc and Portal Biotechnologies Inc were honoured with the New Product Award at the SLAS Conference 2025 in San Diego. The award, presented by the Society for Automation & Drug Screening, recognises pioneering technologies with the potential to transform the industry.
SLASItalian InSimili Srl has been awarded the Ignite Award for the most innovative start-up company in the lab automation sector. The US$5,000 prize was presented by the Society for Laboratory Automation and Screening (SLAS) to the company at SLAS 2025, the leading international conference for lab automation and drug screening
UCB SABelgian UCB SA and British Cancer UK have started a second clinical study within their multi-year partnership to evaluate the safety and tolerable dose of UCB4594 in patients with advanced cancers.
ImmunOs Therapeutics AG Swiss cancer and auto-immunity specialist ImmunOs Therapeutics AG has closed a Series C financing round of US$11m led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures.
AstraZenecaA Phase III trial evaluating AstraZeneca and Daiichi Sankyo’s potential “blockbuster” lung cancer drug Dato-DXd showed no significant improvement over standard chemotherapy. Investors reacted quickly: AstraZeneca’s share price dropped 5% following the announcement.
King's CollegeA new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept for MOv18 IgE.